GHK-Cu Deep-Dive
Also known as: Copper Peptide · Copper Tripeptide-1 · Glycyl-L-Histidyl-L-Lysine Copper
GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. Researchers investigate its modulation of gene expression — over 4,000 human genes have been observed to shift in response to GHK-Cu exposure in vitro — alongside its proposed roles in collagen synthesis, antioxidant signaling, and dermal remodeling.
Plasma Half-Life
Rapid (minutes for systemic forms; topical bioavailability differs)
Logarithmic scale · 15 min mapped
Tissue Residency
Topical residence dependent on formulation and skin barrier
Quick Facts
- Typical dose
- 1–3 mg subcutaneous; topical concentrations 0.05–0.2% in cosmetic research
- Range
- 1 mg – 5 mg subcutaneous; topical 0.01% – 0.5% depending on formulation
- Route
- Subcutaneous injection for systemic research; topical formulation for dermal research applications.
- Cycle pattern
- Subcutaneous protocols commonly run 4–8 week blocks. Topical formulations are typically applied daily or twice daily continuously.
- Primary evidence tier
- Expert
Mechanism of Action
GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. Researchers investigate its modulation of gene expression — over 4,000 human genes have been observed to shift in response to GHK-Cu exposure in vitro — alongside its proposed roles in collagen synthesis, antioxidant signaling, and dermal remodeling.
Researchers investigate GHK-Cu in the broader context of the Skincompound class. The compound's proposed relationship to underlying physiology is typically framed against the Inflammation axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, GHK-Cu's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life Rapid (minutes for systemic forms; topical bioavailability differs)) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
Rapid (minutes for systemic forms; topical bioavailability differs)
Logarithmic scale · 15 min mapped
Tissue Residency
Topical residence dependent on formulation and skin barrier
GHK-Cu has a plasma half-life of approximately Rapid (minutes for systemic forms; topical bioavailability differs). This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, topical residence dependent on formulation and skin barrier. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of GHK-Cualongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from 10,000+ hours of clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians and cosmetic-research practitioners report GHK-Cu as the most-cited copper peptide in skin and hair-follicle research protocols. In protocol audits we've reviewed, two distinct delivery patterns emerge: subcutaneous injection for systemic dermal research and topical formulation for localized skin applications. Practitioners caution that the copper component requires formulation expertise — instability, oxidation, and irritation are reported when poorly formulated topical products are used.
Dosing
1–3 mg subcutaneous; topical concentrations 0.05–0.2% in cosmetic research
Subcutaneous injection for systemic research; topical formulation for dermal research applications.
Cycle
Subcutaneous protocols commonly run 4–8 week blocks. Topical formulations are typically applied daily or twice daily continuously.
Evidence Breakdown
Every finding about GHK-Cuis categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Topical GHK-Cu cosmetic research has the strongest published clinical footprint of any compound on this list, with multiple human studies on dermal applications.
- Practitioner consensus treats GHK-Cu as the canonical copper peptide for both dermal and connective-tissue research stacks.
- Gene-expression research suggests GHK-Cu modulates over 4,000 human genes — emerging work investigates broader systemic applications.
Cycling & Stack Considerations
Cycling Protocol
Subcutaneous protocols commonly run 4–8 week blocks. Topical formulations are typically applied daily or twice daily continuously.
Common Stacks
- •GHK-Cu + BPC-157 (skin + connective tissue)
- •GHK-Cu + TB-500 (dermal + systemic recovery)
- •GHK-Cu solo topical (dermal-focused research protocols)
Interactions & Overlap
- •Vitamin C (topical formulations) — practitioner debate on co-application timing
- •Retinoids (topical) — typically alternated, not co-applied
- •BPC-157, TB-500 — frequently stacked for connective-tissue research
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Wilson's disease or other copper-metabolism disorders — copper component contraindicated
- Active malignancy — gene-expression modulation under research clarification
- Pregnancy and lactation — no human safety data
GHK-Cu FAQs
What is GHK-Cu used for in research?
GHK-Cu is investigated primarily in dermal, hair-follicle, and connective-tissue research applications. The compound's gene-expression modulation profile is also studied in broader systemic-research contexts.
Is GHK-Cu better topical or injected?
Both delivery routes are used in research. Topical formulations dominate dermal cosmetic research; subcutaneous injection is more common in systemic and connective-tissue research protocols.
What is the half-life of GHK-Cu?
Systemic plasma clearance of GHK-Cu is rapid — minutes-scale. Topical residence time depends on formulation, vehicle, and skin barrier. The rapid clearance is one reason topical formulations dominate dermal applications.
Can GHK-Cu be stacked with other peptides?
Yes. The most common practitioner stacks pair GHK-Cu with BPC-157 or TB-500 for combined skin + connective-tissue research protocols.
What concentration of topical GHK-Cu is used in cosmetic research?
Cosmetic research formulations commonly cite 0.05–0.2% concentrations. Higher concentrations (up to 0.5%) appear in some research protocols but require careful formulation to avoid copper instability and irritation.
Are there side effects from GHK-Cu?
Topical applications can cause irritation if poorly formulated. Systemic injection has limited human safety data. Individuals with copper-metabolism disorders should not use GHK-Cu in any form.
How does GHK-Cu compare to retinoids?
They operate on different mechanisms. Retinoids drive cellular turnover via retinoic acid receptors; GHK-Cu is investigated for broader gene-expression modulation. Practitioner protocols typically alternate rather than co-apply the two.
Related Compounds
Track your GHK-Cu protocol in DoseCraft
The PK-aware protocol builder models Rapid (minutes for systemic forms; topical bioavailability differs) decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.